See Remarks · Spyre Therapeutics, Inc. · Spyre Therapeutics, Inc. — Stock Option (Right to Buy)
Side
A
Value
—
Shares
140.0K
Price
—
Executed
Jan 9, 2026
Disclosed
Jan 13, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 9 executedJan 13, 2026 disclosed
SYRE · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Spyre Therapeutics, Inc. — Stock Option (Right to Buy)
Ticker
SYRE
Shares
140.0K
Price per share
$0
Execution date (reported)
Jan 9, 2026
Owned after transaction
140.0K shares
Days from execution to publication
4
What this establishes
King-Jones Heidy filed this Form 4 reporting a grant or award of SYRE on Jan 9, 2026. It became public on Jan 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
See Remarks
King-Jones Heidycik:0001794898
Issuer
Spyre Therapeutics, Inc.cik:0001636282
Revision history · 0
No field has changed since this record was first ingested.
